Statement of Changes in Beneficial Ownership (4)
2020年2月13日 - 7:23AM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Sachdev Amit |
2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA
[
VRTX
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) EVP, Chief Patient Officer |
(Last)
(First)
(Middle)
C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE |
3. Date of Earliest Transaction
(MM/DD/YYYY)
2/10/2020 |
(Street)
BOSTON, MA 02210
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 2/10/2020 | | F | | 12215 | D | $240.95 | 59268 | D | |
Common Stock | 2/11/2020 | | S(1) | | 1000 | D | $243.53 (2)(3) | 58268 | D | |
Common Stock | 2/11/2020 | | S(1) | | 3426 | D | $245.05 (3)(4) | 54842 | D | |
Common Stock | 2/11/2020 | | S(1) | | 4320 | D | $245.99 (3)(5) | 50522 | D | |
Common Stock | 2/11/2020 | | S(1) | | 1821 | D | $246.88 (3)(6) | 48701 | D | |
Common Stock | 2/11/2020 | | S(1) | | 2103 | D | $247.98 (3)(7) | 46598 | D | |
Common Stock | 2/11/2020 | | S(1) | | 400 | D | $248.73 (3)(8) | 46198 | D | |
Common Stock | | | | | | | | 16190 | I | Held in Trust |
Common Stock | | | | | | | | 882 | I | 401(k) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. |
(2) | Open market sales reported on this line occurred at a weighted average price of $243.53 (range $242.88 to $243.86). |
(3) | Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
(4) | Open market sales reported on this line occurred at a weighted average price of $245.05 (range $244.50 to $245.47). |
(5) | Open market sales reported on this line occurred at a weighted average price of $245.99 (range $245.50 to $246.45). |
(6) | Open market sales reported on this line occurred at a weighted average price of $246.88 (range $246.53 to $247.39). |
(7) | Open market sales reported on this line occurred at a weighted average price of $247.98 (range $247.55 to $248.50). |
(8) | Open market sales reported on this line occurred at a weighted average price of $248.73 (range $248.60 to $248.82). |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Sachdev Amit C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON, MA 02210 |
|
| EVP, Chief Patient Officer |
|
Signatures
|
/s/ Omar White, Attorney-in-Fact | | 2/12/2020 |
**Signature of Reporting Person | Date |
Vertex Pharmaceuticals (NASDAQ:VRTX)
過去 株価チャート
から 6 2024 まで 7 2024
Vertex Pharmaceuticals (NASDAQ:VRTX)
過去 株価チャート
から 7 2023 まで 7 2024